ストックスクリーナーアプリを入手
6.71
2.33%
-0.16
アフターアワーズ：
6.79
0.08
+1.19%
Organon Co (OGN) 最新ニュース
Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo
Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan
Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat
Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan
Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan
Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan
Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan
Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan
Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st
Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews
KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com
KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages - MarketBeat
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis - Bitget
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
OGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Organon presents sleep improvement data for VTAMA cream in children By Investing.com - Investing.com Australia
Organon presents sleep improvement data for VTAMA cream in children - Investing.com
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN - MarketBeat
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com Nigeria
Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit - Sahm
Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth - TipRanks
Organon & Co. (NYSE:OGN) Trading Down 6.3%Time to Sell? - MarketBeat
Organon & Co. (OGN) Stock Analysis: Navigating a Potential Upside Amidst a Challenging Landscape - DirectorsTalk Interviews
Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays - MarketBeat
Organon price target raised to $8 from $7.50 at Barclays - TipRanks
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals By Investing.com - Investing.com India
Organon & Co. (OGN) posts FY adjusted EPS of $3.66, EBITDA margin at 30.7% - MSN
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% - Insider Monkey
Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus - TechStock²
Organon Signs Deal for Global Rights to Sebela's Miudella Intrauterine Device - marketscreener.com
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals - Investing.com
Organon Licenses MIUDELLA® to Enhance Women's Health Commitment - Intellectia AI
Organon enters into agreement to license Miudella® - marketscreener.com
First hormone-free copper IUD in 40 years lands $27.5M Organon deal - Stock Titan
Organon (OGN) Is Up 9.6% After Weaker 2025 Earnings And New 2026 Revenue GuidanceWhat's Changed - simplywall.st
Organon rises after update on independent review - MSN
Organon climbs 6% after audit clears company of wrongdoing - MSN
Organon Shares Rally as Investigation Clears Company of Wrongdoing - AD HOC NEWS
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Up 6.6%What's Next? - MarketBeat
Sector Update: Health Care - marketscreener.com
Organon Says Audit Review of Biosimilar Purchases Finds No Issues - marketscreener.com
Organon & Co. audit committee completes review of biosimilar purchase timing By Investing.com - Investing.com South Africa
Organon & Co. audit committee completes review of biosimilar purchase timing - Investing.com Nigeria
Organon rises after update on independent review (OGN:NYSE) - Seeking Alpha
Organon Audit Review Finds No Issues, 10-K On Track - TipRanks
Organon shares jump 6% after audit finds no misconduct By Investing.com - Investing.com India
Organon shares jump 6% after audit finds no misconduct - Investing.com
Organon (OGN) audit review finds no misconduct, plans timely 2025 10-K - Stock Titan
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
MACD Signal: Is Organon Co subject to activist investor interestEarnings Growth Summary & Weekly High Return Stock Opportunities - baoquankhu1.vn
Ex-Dividend Reminder: Murphy USA, American States Water and Organon - Nasdaq
5 Revealing Analyst Questions From Organon's Q4 Earnings Call - Finviz
0.04%
1.48%
大文字化:
|
ボリューム (24 時間):